Abstract
References
1.
Bliss
M R
(1981 ) British Medical Journal 283 , 203 –206 .
2.
Breckenridge
A M
(1981 ) In: Risk-Benefit Analysis in Drug Research . Ed.
Cavalla
J F
. MTP Press , Lancaster ; pp 75 –81 .
3.British Journal of Clinical Pharmacology (1978 ) 5 , 3 –5 .
4.British Journal of Hospital Medicine (1981 ) 25 , 5 .
5.
Cavalla
J.F
(1981 ) In: Risk-Benefit Analysis in Drug Research . Ed.
Cavalla
J F
. MTP Press , Lancaster ; chapters IX-X.
6.
Curry
S H
(1977 ) In: Topics in Therapeutics , vol 3 . Ed.
Shanks
R G
. Pitman Medical , Tunbridge Wells ; pp 38 –51 .
7.
Griffin
J P
Long
J R
(1981 ) British Medical Journal 283 , 477 –479 .
8.
Koch-Weser
J
(1977 ) In: Topics in Therapeutics , vol 3 . Ed.
Shanks
R G
. Pitman Medical , Tunbridge Wells ; pp 61 –75 Lancet (1981) i, 1297–1298.
9.
Richens
A
(1975 ) In: Clinical Pharmacology of Anti-Epileptic Drugs . Ed.
Schneider
H
Springer-Verlag , Berlin ; p 293 .
10.
Rose
G
(1981 ) British Medical Journal 282 , 1847 –1851 .
11.
Turner
P
(1976 ) In: Topics in Therapeutics , vol 2 . Ed.
Turner
P
. Pitman Medical , Tunbridge Wells ; pp 83 –86 .
12.
Turner
P
(1978 ) In: Recent Advances in Clinical Pharmacology , vol 1 . Ed.
Turner
P
Shand
D G
. Churchill-Livingstone , Edinburgh ; pp 11 –16 .
13.
Turner
P
(1981 ) British Journal of Hospital Medicine 25 , 309 .
14.World Health Organization (1980 ) Lancet ii , 379 –385 .